Published on 30/11/2025

Short-Run SPC for ATMP: What Works

In the rapidly evolving landscape of Advanced Therapy Medicinal Products (ATMPs), the imperative for optimal viral clearance validation, particularly in the context of short-run processes and Quality Assurance strategies, cannot be overstated. This comprehensive guide aims to elucidate effective practices for establishing robust short-run Process Performance Qualification (PPQ) frameworks and Critical Process Variable (CPV) tailoring specific to ATMPs. Through an emphasis on effective use of spiking studies and closed/single-use systems, along with stringent aseptic controls, this article serves as a valuable resource for pharmaceutical professionals dealing with biologics and ATMPs.

Understanding ATMPs and their Regulatory Landscape

Advanced Therapy Medicinal Products, inclusive of gene therapies, somatic cell therapies, and tissue-engineered products, are pivotal in addressing multifaceted medical challenges. The regulatory frameworks governing these products are rigorously defined by authorities such as the Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). Familiarity with guidelines—such as the FDA’s Guidance for Industry on Process Validation—is essential for professionals involved in the development and commercialization of ATMPs.

Moreover, the International Council for Harmonisation (ICH), through documents like ICH Q5A(R2), outlines the expectations for viral safety in biotechnological products, including methods for performance qualification and validation of viral clearance processes. Understanding these documents aids companies in ensuring compliance while maintaining safety and efficacy in their products.

Key Elements of ATMP Development and Validation

The development and validation of ATMPs encompass several critical elements:

• Process Development: Establishing a consistent and reproducible process that can deliver therapeutic benefits in a safe manner.
• Viral Clearance Validation: Implementing a stringent validation process to ensure the removal or inactivation of potential viral contaminants during manufacturing.
• Potency Identity Quality Controls (CQAs): Defining parameters to assure the product’s potency and identity across production batches is crucial.
• Chain of Identity Custody (COI): Developing mechanisms to maintain the identity of biologics throughout the production process ensures compliance with regulatory expectations.

Continuous monitoring and adaptation of these elements within the PPQ framework will enable manufacturers to respond effectively to regulatory changes and evolving scientific knowledge.

Pilot Scale and Short-Run SPC Considerations

Pilot scale and short-run production scenarios present unique challenges, necessitating tailored strategies to facilitate efficient validation. In these contexts, evidence of process performance and reliability must be established while acknowledging the inherent variability of biologic products.

Defining the Short-Run Approach

In short-run SPC, the focus is on achieving controlled operational conditions that can be statistically monitored to yield reliable data pertinent to the process performance. This involves:

• Process Design and Risk Assessment: Comprehensive evaluations to identify potential risks associated with the manufacturing process.
• Spiking Studies: Conducting carefully designed spiking studies to evaluate the efficacy of viral clearance operations. This includes selecting appropriate model viruses that represent a worst-case scenario for contamination.
• Validation of Closed Systems: The implementation of closed systems is critical to reduce the risk of contamination. Regulatory bodies including the EMA have endorsed these methods within their Aseptic Controls Annex 1.
• Utilizing Single-Use Systems: Leveraging single-use technologies can significantly streamline operations and enhance the biological safety of ATMP manufacturing.

Implementing a Validation Strategy

The steps outlined below serve as a comprehensive guide to establishing an effective validation strategy in the context of PPQ for short-run ATMP manufacturing.

Step 1: Process Characterization

The first step in formulating a validation strategy is process characterization. This entails a detailed understanding of the manufacturing processes and the variables that influence the final product quality. The characterization phase includes:

• Identifying Critical Quality Attributes (CQAs): For ATMPs, CQAs must reflect aspects such as safety, identity, strength, and purity. These attributes must be monitored to ensure compliance with regulatory standards.
• Process Mapping: Constructing a map of the entire process helps visualize critical steps and identify potential sources of variability that may impact product quality.
• Risk Assessment: Conducting risk assessments using methodologies such as Failure Mode and Effects Analysis (FMEA) allows for the identification of potential failure points and their associated severity in the production process.

Step 2: Developing a Validation Master Plan (VMP)

A Validation Master Plan (VMP) is an essential document that outlines the overall strategy for validation activities. The VMP should include:

• Scope and Objectives: Clearly delineate the scope of validation efforts and the intended objectives.
• Resource Allocation: Specify the personnel and materials required for the validation process, ensuring that all personnel are adequately trained.
• Timelines: Establish clear timelines for each phase of validation to facilitate efficient execution and adherence to project deadlines.
• Responsibility Matrix: Include a matrix that designates responsibilities across teams, ensuring accountability at all levels.

Step 3: Execution of Validation Activities

Upon completing the VMP, the next step is executing the validation activities aligned with the previously defined plans:

• Conducting Spiking Studies: Spiking studies must be designed to simulate the worst-case scenarios for viral contamination, evaluating the effectiveness of the viral clearance measures in the manufacturing process.
• Documenting Results: Thorough documentation is imperative at this stage; all findings from the spiking studies and viral clearance tests should be detailed meticulously to provide a clear reference for regulatory review.
• Closed and Single-Use systems validation: Validate the construction and operation of closed systems and single-use systems, including assessments of their impact on contamination and overall product quality.

Step 4: Data Analysis and Interpretation

After the execution of validation activities, thorough analysis of collected data is required for robust interpretation:

• Statistical Analysis: Employ statistical methods to evaluate the data to establish trends and identify any deviations from expected results. Utilizing control charts can help monitor ongoing performance.
• Performance Review: Review the validation outcomes against predefined acceptance criteria to ensure that the validation objectives were met. This assessment should include an analysis of the implications of findings on product safety and efficacy.
• CQA Impact Assessment: Determine if and how variations in CQAs were affected by process conditions and whether relevant adjustments are necessary.

Step 5: Finalizing Validation Documentation

The final step is preparing the validation documentation that encapsulates all aspects of the validation process:

• Final Validation Report: Prepare a comprehensive validation report detailing the methodologies employed, results obtained, and conclusions drawn from the validations carried out during the PPQ process. This document serves as critical evidence of compliance for regulatory submissions.
• Change Control Procedures: Implement change management protocols to ensure robust procedures are in place for future modifications to the process, thereby safeguarding product integrity.
• Review and Approval: Ensure all validation documentation undergoes a thorough review process before approval by designated quality management personnel, in compliance with applicable regulations.

Conclusion

Implementing a successful short-run SPC for ATMP involves an intricate balance of process understanding, validation strategies, and adherence to regulatory expectations. By effectively incorporating spiking studies, closed systems, and single-use technologies while ensuring compliance with global regulations, manufacturers can significantly enhance the reliability and safety of their products. This approach positions companies to not only meet regulatory criteria but also to excel in delivering high-quality therapeutic products that address patient needs efficiently.